Latest Articles

Publication Date
HOXC4 promotes proliferation of endometriotic stromal cells via the SLIT2-ROBO1 axis.

Current interventions for endometriosis mainly involve hormone therapies but have limited efficacy and unacceptable side effects due to the lack of selectivity to distinguish between endometriosis and endometrial tissues. Elucidating …

Published: Aug. 27, 2025, midnight
Nanotechnology strategies for endometrium health: Are we on the right track?

The endometrium is a vital mucosal tissue which undergoes cyclical regeneration, differentiation, and remodeling upon hormonal, cellular, and molecular signaling networks. Dysregulation of these processes can trigger a range of …

Published: Aug. 27, 2025, midnight
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork

Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork

Published: Aug. 26, 2025, 10:07 p.m.
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest

Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value AInvest

Published: Aug. 26, 2025, 7:31 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology

FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology

Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News

Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News

Published: Aug. 26, 2025, 6:04 p.m.
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest

Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value AInvest

Published: Aug. 26, 2025, 5:39 p.m.
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer - Curetoday

Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer Curetoday

Published: Aug. 26, 2025, 4:06 p.m.
Olaparib Maintenance in Advanced Endometrial Cancer Trial - BIOENGINEER.ORG

Olaparib Maintenance in Advanced Endometrial Cancer Trial BIOENGINEER.ORG

Published: Aug. 26, 2025, 3:07 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive

Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive

Published: Aug. 26, 2025, 3:01 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!